Whitfield Advises GTCR-Backed Corza Medical on Divestiture of Biosurgery Business Unit to EQT
Whitfield represented GTCR-backed Corza Medical, a leading global medical technology company, on its agreement to sell its Biosurgery business unit, including the TachoSil® product portfolio, to EQT. Financial terms of the agreement were not disclosed. The transaction is expected to close during Q4 2026, subject to customary closing conditions and regulatory approvals.
The Whitfield team included corporate lawyers Christopher Thomas, Kyle McHugh, Jacob Traff and Andrew McAlpine; debt finance lawyers Tom Dobleman and Patrick Loughery; and tax lawyers Mike Carew and Adam Kool.
